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Abstract Pulmonary arterial hypertension (PAH) is
a life-threatening condition characterized by progres-
sive elevation in pulmonary artery pressure (PAP) and
total pulmonary vascular resistance (TPVR). Recent
advances in imaging techniques have allowed the
development of new echocardiographic parameters to
evaluate disease progression. However, there are no
reports comparing the diagnostic performance of
these non-invasive parameters to each other and to
invasive measurements. Therefore, we investigated
the diagnostic yield of echocardiographically derived
TPVR and Doppler parameters of PAP in screening
and measuring the severity of PAH in a rat model.
Serial echocardiographic and invasive measurements
were performed at baseline, 21 and 35 days after
monocrotaline-induction of PAH. The most challeng-
ing echocardiographic derived TPVR measurement
had good correlation with the invasive measurement
(r = 0.92, P \ 0.001) but also more simple and novel
parameters of TPVR were found to be useful although
the non-invasive TPVR measurement was feasible in
only 29% of the studies due to lack of sufficient
tricuspid valve regurgitation. However, echocardio-
graphic measures of PAP, pulmonary artery flow
acceleration time (PAAT) and deceleration (PAD),
were measurable in all animals, and correlated with
invasive PAP (r = -0.74 and r = 0.75, P \ 0.001
for both). Right ventricular thickness and area corre-
lated with invasive PAP (r = 0.59 and r = 0.64,
P \ 0.001 for both). Observer variability of the
invasive and non-invasive parameters was low except
in tissue-Doppler derived isovolumetric relaxation
time. These non-invasive parameters may be used to
replace invasive measurements in detecting successful
disease induction and to complement invasive data in
the evaluation of PAH severity in a rat model.
Keywords Pulmonary hypertension 
Echocardiography  Monocrotaline 
Total pulmonary vascular resistance 
Pulmonary artery pressure  PAAT  PAD
Introduction
Pulmonary hypertension (PH) is a progressive and
life threatening condition characterized by a progres-
sive increase in pulmonary vascular resistance result-
ing in right heart failure and death. PH is classified in
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five subgroups according to etiology, of which one is
pulmonary arterial hypertension (PAH) [1]. Prognosis
in idiopathic PH, a subgroup of PAH, remains poor
[2]. PAH is defined by a mean pulmonary artery
pressure (PAP) [25 mmHg at rest or [30 mmHg
during exercise [3]. Doppler echocardiography allows
indirect measurement of PAP from valvular regurgi-
tation and detects corresponding changes in right
heart morphology and function [4–6]. In clinical
practice, right heart catheterization is mandatory to
confirm the presence of PAH and to test vasoreac-
tivity of the pulmonary circulation [7].
Echocardiographically derived peak and mean
PAP have been reported to correlate (r = 0.73–
0.94) with invasive measurements in humans [8–10].
However, these measurements require the presence of
right-sided valvular regurgitation. Tricuspid valve
regurgitation (TR) can be detected in only 39–86% of
patients and in only 44–96% of these cases does the
regurgitation produce enough signal for pressure
measurement to be made possible [4]. Detecting a
good signal from pulmonary valve regurgitation also
requires technical competence but has approximately
the same yield as TR signals [11]. Furthermore, PAP
measurement without flow information can be mis-
leading especially in cases with elevated PAP due to
high cardiac output but normal pulmonary vascular
resistance (PVR). Therefore, additional non-invasive
parameters for evaluation of PAH are much needed.
Echocardiographically derived PVR has proven to
be a valuable parameter [12, 13]. However, this
measurement also requires the presence of TR. Tissue
Doppler derived isovolumetric relaxation time
(IVRT’) of the right ventricle (RV) predicts elevated
PAP in humans [14]. Pulmonary artery acceleration
time (PAAT) correlated (r = 0.84–0.89) with inva-
sive PAP especially in mild to moderate PAH and
was prognostic as well [15]. However, except for
PAAT, all other measurements require acceptable
Doppler image quality. Three different velocity
profiles (normal round-shaped, intermediate and
triangular) were characterized corresponding to the
severity of PAH [16, 17] (Fig. 1). Under normal
conditions, pulmonary artery flow velocity increases
and decreases slowly and symmetrically. In PAH,
flow velocity increases and decreases rapidly [18, 19]
due to increased right ventricular stroke work and
stiffness in the pulmonary artery leading to altered
velocity profiles. The greatest difference in these flow
profiles exists during the early deceleration period.
However, it has not been shown whether quantifica-
tion of the pulmonary artery flow deceleration (PAD)
is useful for detecting PAH or measuring its severity.
Furthermore, observer related variability of the
invasive and noninvasive parameters of PAH in rats
is relatively unknown.
Fig. 1 Progression of PAH demonstrated by echocardiogra-
phy at baseline, and 21 and 35 days after MCT induction.
Columns represent temporal phases (baseline, day 21, and day
35) and rows five different imaging windows: (1) high
parasternal short-axis view is used to detect pulmonary artery
flow by pulsed-wave Doppler, right ventricular remodeling by
(2) apical four-chamber view, (3) parasternal long-axis, (4)
parasternal short-axis views using B-mode (all end-diastolic),
and right ventricular thickness by (5) parasternal long-axis
through aortic valve using M-mode. Upper row demonstrates
different types of pulmonary artery flow profiles regarding to
the severity of pulmonary hypertension. Normal, round-shaped
flow profile (baseline), intermediate type flow profile with a
sharp peak at early systole, decreased acceleration time and
increased deceleration (day 21) and triangular flow profile with
mid-systolic notching (day 35). Apical four-chamber and both
parasternal views show progressive right ventricular dilatation
with concomitant decrease of left ventricle. Parasternal long-
axis images through aorta using M-mode show progressing
right ventricular hypertrophy
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We investigated the diagnostic yield of echocar-
diographically derived TPVR and echocardiographic
parameters of PAP in screening PAH in a rat model.
Furthermore, we studied whether these non-invasive
measurements can be used to measure the severity of
PAH by comparing them to invasive measurements.
We hypothesized that the echocardiographic param-
eters TPVR, IVRT’, PAAT, PAD, right ventricular
area and thickness reliably predict the severity of
PAH and are reproducible.
Methods
Six-week old female RNU-1 (Charles river) nude rats
(n = 28) were used according to our protocol
approved by Institutional animal care and use com-
mittee (IACUC). Pulmonary hypertension was
induced using intraperitoneal injection of monocro-
taline (MCT) (Sigma–Aldrich, St. Louis, MO) with a
dose of 75 mg/kg. MCT was dissolved in HCl
(hydrochloric acid), diluted with distilled water and
administered after adjusting the pH to 7.4. MCT is a
pyrrolized alkaloid derived from Crotalia spectabilis
and its administration into the intraperitoneal cavity
is associated with increased pulmonary arterial
pressure, increased medial wall thickening, and RV
hypertrophy [20, 21]. The MCT-induced PAH model
is widely used and has shown similarities to human
idiopathic PAH [22, 23]. Right heart catheterization
and echocardiography were performed within the
same day under general anesthesia (2% isofluorane/
oxygen 1 l/min). The animals were placed on a
heating pad to maintain body temperature at 37–38C
throughout the studies. Studies were performed at
baseline, 21 and 35 days after MCT injection.
Invasive measurements by right heart
catheterization
Lidocaine (6 mg/kg) was administered subcutane-
ously into the neck of the animal and the right or left
external jugular vein was isolated. A 2F microtip
catheter (Millar Instruments) was connected via a
pressure control unit (Millar Instruments, Houston,
TX) to a physiological recorder (Powerlab ML786)
and viewed using Chart5 computer software (ADIn-
struments, Colorado Springs, CO). The catheter was
guided into the RV to obtain pressure measurements
after calibration. Pulmonary valve pathology was
excluded at baseline using echocardiography and
therefore right ventricular systolic pressure (RVSP) is
similar to the systolic PAP. An average of 15–20
pressure cycles was utilized to obtain final pressure
value. Systolic PAP values were employed to deter-
mine mean PAP using the following experimental
formula: Mean PAP (in mmHg) = 0.61*systolic
PAP ? 2 [24]. Invasive TPVR in dynscm-5 was
calculated using the following formula: 80 * mean
PAP (in mmHg)/cardiac output (in liters).
Echocardiography
Transthoracic echocardiography was performed by
Sequoia C 256 ultrasound device (Acuson Inc.,
Mountain View, California) with a 15.0 MHz linear
or a 3.5 MHz cardiac transducer. Presence of TR was
assessed from color Doppler images using a
15.0 MHz transducer. Tricuspid valve was graded
as normal if TR was not observed, mild, moderate
and severe when regurgitation jet was visually\20%,
20–50% or [50% of the right atrial area, respec-
tively. If TR was observed, the regurgitation velocity
was assessed by using a 3.5 MHz transducer with
continuous wave Doppler. Pulmonary artery flow was
measured using pulsed wave Doppler with a sample
gate of 1.0 mm at pulmonary valve level but signal
for PAAT and PAD measurements were achieved
from the right ventricular outflow tract and opening
and closing clicks of the pulmonary valve were
avoided. By combining pulmonary artery velocity–
time integral, pulmonary artery area and heart rate,
echocardiographically derived cardiac output was
determined as published earlier [25]. Tissue Doppler
was measured from basal lateral wall of the right
ventricle in a four-chamber view with a gate of
1–2 mm. Echo-TPVR was measured using four dif-
ferent ways: Echo-TPVR formula-1 (peak TR velocity/
right ventricular outflow tract velocity time integral
(RVOT VTI)) [13], Echo-TPVR formula-2 (TPVR
(in dynscm-5) = 80 * mean PAP (in mmHg)/
cardiac output (in liters), in which mean PAP is
determined from systolic PAP as outlined previously,
Echo-TPVR formula-3 (PAAT/RVOT VTI), and
Echo-TPVR formula-4 (PAD/RVOT VTI). IVRT’
was defined as the interval from the end of Sm wave
to the beginning of Ea wave [26]. PAAT was defined
as the interval from the onset to the maximal velocity
Int J Cardiovasc Imaging (2010) 26:509–518 511
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of forward pulmonary artery flow and PAD as the
first linear deceleration period after maximal velocity.
Right ventricular thickness was measured at diastole
from parasternal long axis view using M-mode.
Apical four-chamber view was employed to measure
end-diastolic right ventricular area.
Statistical analysis
Statistical analysis was performed using either SPSS
16 (SSPP Inc, Chicago, IL, USA) or SAS (SAS
Institute, Cary, NC, USA). Statistical difference
between the parameters at baseline, 21 and 35 days
after PAH induction was assessed with repeated-
measures analysis of variance with Tukey’s correction,
except for those without successful measurements
at baseline, which were assessed by paired t-test.
Pearson or Spearman correlation coefficients were
appropriately calculated. Bland–Altman method was
used for comparing parameters when appropriate
[27]. To obtain intraobserver and interobserver var-
iability of the invasive and noninvasive parameters,
ten studies were analyzed by two blinded reviewers.
Observer variability is expressed using coefficient of
variation (CV), mean difference and intraclass corre-
lation [28]. CV for repeated measurements was
calculated by dividing SD with a mean and expressed
as percentage values. Mean difference (%) was
calculated using the following formula (|measure-
ment 1 - measurement 2|)/((measurement 1 ? mea-
surement 2)/2) * 100. ROC curves were generated to
explore an optimal cut-off value of the studied
parameters to discriminate animals with PAH from
non-PAH animals. An area under each ROC curve
(AUC) was calculated. Positive and negative predic-
tive values, sensitivity, specificity and accuracy were
calculated using standard formulas. P-value less than
0.05 was considered significant. The results are
expressed as mean ± SD.
Results
A total of 75 echocardiographies were performed and
analyzed in rats with variable degrees of PAP at the
combined time-points of baseline, 21 and 35 days
after MCT injection. Twenty-eight animals had echos
performed at baseline and at 21 days. However, only
19 animals had the echocardiography at day 35 due to
the mortality associated with significant PAH.
Pulmonary artery flow (Fig. 1) was measured suc-
cessfully by echocardiography in all animals whereas
invasive PAP measurement was technically feasible
in only 62 out of 75 (83%) studies, mostly due to the
technically challenging nature of accessing murine
right ventricle in PAH. There was no detectable TR in
any of the study animals at baseline. At day 35, up to
84% of the animals had TR. Ten mild, ten moderate
and 14 severe TR were noted in total. Detailed
hemodynamic data is presented in Table 1.
The correlation between echocardiographically
derived TPVR with invasive TPVR measurements
were as follows: r = 0.85, P \ 0.001, r = 0.92,
P \ 0.001, r = 0.08, P = 0.56 and r = 0.70,
P \ 0.001 for Echo-TPVR formula 1, 2, 3 and 4,
respectively (Fig. 2a, b). Echo-derived TPVR using
formula 1 and 2 was measurable in only 23% (14 out
of 62) of the studies with successful invasive
measurements; the rest of the animals had an
insufficient degree of TR for evaluation. Figure 2c
demonstrates Bland–Altman plot between Echo-
TPVR formula-2 and invasive TPVR measurement.
Additionally, one of the TPVR measurement pair is
noted to be radically different than the others but the
observed correlations between echo-TPVR-1 and 2
versus invasive-TPVR are r = 0.67, P = 0.005 and
r = 0.70, P \ 0.001, respectively, even after exclud-
ing this pair. The measurement of IVRT’ had a weak
correlation (r = 0.38, P = 0.02) with invasive PAP
and it was measurable in 56% of the studies. PAAT
(r = -0.74, P \ 0.001) and PAD (r = 0.75,
P \ 0.001) had relatively good correlations with
invasive PAP (Fig. 3a, b). Even though echocardio-
graphically derived systolic PAP had a minimal mean
difference of 5.4 ± 12.8 mmHg compared to inva-
sive PAP, significant correlation (r = 0.38,
P = 0.18) was not observed between the methods
due to small range of observed PAPs using this echo
method. Both anatomical measures, right ventricular
thickness and right ventricular area, correlated with
invasive PAP (r = 0.59 and r = 0.64, P \ 0.001 for
both).
Intraobserver and interobserver variabilities of the
studied parameters are presented in Table 2. Intraob-
server and interobserver variability of the invasive
PAP expressed as coefficient of variation was
1.4 ± 2.0 and 1.3 ± 1.4%. The intraobserver and
interobserver variability values for all the non-
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invasive parameters ranged between 2.6 ± 3.5 and
20.6 ± 27.2%, respectively (Table 2). Observer
related variability of invasive TPVR was 7.2 ± 9.3
and 9.1 ± 8.6%. Echo-TPVR formula-1 had lower
observer related variability compared to echo-TPVR
formula-2.
Diagnostic performance of echocardiographic
parameters to detect pulmonary hypertension (mPAP
[25 mmHg) is presented in Table 3. Optimal cut-off
values and areas under curve were 28 ms (AUC
0.943) for PAAT, 11.8 m/s2 (AUC 0.931) for PAD,
0.56 mm (AUC 0.887) for RV thickness and
0.225 cm2 (AUC 0.907) for RV area, respectively.
PAAT \28 ms had the best diagnostic value when
accounting all non-invasive parameters. We created
two new algorithms of pulmonary flow by combining
PAAT \28 ms and PAD [11.8 m/s2 values
(Table 3). The algorithm of PAAT \28 ms and
PAD [11.8 m/s2 has the best specificity of 97.3%
and PAAT\28 ms has the best sensitivity of 86.4%.
Table 1 Characteristics of rats at baseline and 21 and 35 days after MCT injection for induction of pulmonary arterial hypertension
Baseline
(n = 28)
Day 21
(n = 28)
Day 35
(n = 19)
Baseline vs.
day 21
Day 21 vs.
day 35
Baseline vs.
day 35
Weight (g) 150.0 ± 26.9 170.9 ± 18.0 184.6 ± 24.7 P = 0.04 P = 0.13 P \ 0.001
Heart rate (bpm) 373 ± 32 344 ± 41 304 ± 43 P = 0.02 P = 0.002 P \ 0.001
Invasive systolic PAP (mmHg) 29.6 ± 3.7 39.5 ± 15.5 65.3 ± 14.9 P = 0.01 P \ 0.001 P \ 0.001
Invasive mean PAP (mmHg) 20.1 ± 2.3 26.1 ± 9.5 41.8 ± 9.1 P = 0.01 P \ 0.001 P \ 0.001
Invasive TPVR (104*dynscm-5) 2.3 ± 0.8 3.5 ± 2.3 6.4 ± 3.9 P = 0.24 P \ 0.01 P \ 0.001
Tricuspid regurgitation (%) 0% 64% 84% P \ 0.001 P = 0.15 P \ 0.001
Echo systolic PAP (mmHg) NA 66.4 ± 18.8 83.6 ± 16.2 NA P = 0.03 NA
Echo TPVR (ms-1m) NA 142 ± 61 149 ± 60 NA P = 0.57 NA
Echo TPVR (104*dynscm-5) NA 7.7 ± 2.8 9.2 ± 5.9 NA P = 0.52 NA
IVRT’ (ms) 20.2 ± 9.4 20.1 ± 16.9 29.0 ± 18.3 P = 1.00 P = 0.29 P = 0.29
Pulmonary artery acceleration time (ms) 36.3 ± 5.5 27.7 ± 6.3 21.7 ± 4.5 P \ 0.001 P \ 0.01 P \ 0.001
Pulmonary artery deceleration (m/s2) 7.3 ± 2.4 11.7 ± 6.6 16.6 ± 4.7 P \ 0.01 P \ 0.01 P \ 0.001
Right ventricular cardiac output (ml) 77.7 ± 20.6 65.5 ± 21.8 63.0 ± 22.8 P = 0.12 P = 0.93 P = 0.08
Right ventricular area (cm2) 0.18 ± 0.04 0.26 ± 0.09 0.31 ± 0.10 P = 0.02 P \ 0.001 P \ 0.001
Right ventricular thickness (mm) 0.42 ± 0.07 0.55 ± 0.17 0.77 ± 0.18 P = 0.02 P = 0.10 P \ 0.001
All data is presented as mean ± SD
See Methods for calculations
PAP pulmonary artery pressure; TPVR total pulmonary vascular resistance; NA not available; IVRT’ tissue Doppler derived
isovolumetric relaxation time of the right ventricle
Fig. 2 Correlations between TPVR by right heart catheteriza-
tion and two different echocardiographic techniques. Echo-
TPVR (formula-1) was calculated by dividing tricuspid
regurgitation velocity from pulmonary artery velocity time
integral (a), Echo-TPVR (formula-2) was calculated by the
following formula (Echo TPVR = 80 * mean PAP in mmHg/
cardiac output in liters) (b). Invasive TPVR was calculated
using the previous formula and the mean PAP was derived
from systolic PAP using previously validated formula [24], and
Bland–Altman plot between Echo-TPVR formula-2 and
invasive TPVR measurement (c)
Int J Cardiovasc Imaging (2010) 26:509–518 513
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Discussion
We have demonstrated that pulmonary artery flow is
readily detectable using echocardiography and can be
used as a screening tool for the evaluation of PAH in
a rat model. Furthermore, we have shown that
parameters such as echo-TPVR, PAAT, and PAD
are associated with the severity of PAH. Since rat
models are increasingly used in studies evaluating
various therapeutic interventions for PAH, these
non-invasive parameters allow identification and
quantification of disease progression at multiple
time-points, replacing or at least complementing
invasive data. Furthermore, we have developed
Fig. 3 Correlation between
invasive (right heart
catheterization)
measurement of PAP and its
estimation from
echocardiographically
derived pulmonary artery
acceleration time (a) and
pulmonary artery
deceleration (b)
Table 2 Intraobserver and interobserver variability of the invasive and noninvasive parameters of pulmonary arterial hypertension
CV% Mean difference
(range) %
Intraclass correlation
(P-value)
Intraobserver variability
Invasive mean PAP (mmHg) 1.4 ± 2.0 1.3 (-6.4–2.4) 0.99 (P \ 0.001)
Invasive TPVR (104*dynscm-5) 7.2 ± 9.3 12.3 (-10.7–25.4) 0.90 (P \ 0.001)
Echo systolic PAP (mmHg) 4.9 ± 3.3 4.6 (-10.8–7.9) 0.97 (P \ 0.001)
Echo TPVR (ms-1m) 5.8 ± 4.6 5.4 (-8.0–14.7) 0.95 (P \ 0.001)
Echo TPVR (104* dynscm-5) 10.1 ± 12.2 9.5 (-24.2–31.0) 0.85 (P \ 0.001)
IVRT’ (ms) 7.6 ± 7.0 8.1 (-13.1–15.2) 0.96 (P \ 0.001)
PAAT (ms) 4.8 ± 3.0 4.6 (-7.5–6.6) 0.90 (P \ 0.001)
PAD (m/s2) 10.2 ± 6.7 9.9 (-23.5–9.5) 0.94 (P \ 0.001)
Right ventricular area (cm2) 11.3 ± 9.4 8.8 (-18.3–16.4) 0.90 (P \ 0.001)
Right ventricular thickness (mm) 8.1 ± 7.2 5.2 (-16.1–13.2) 0.95 (P \ 0.001)
Interobserver variability
Invasive mean PAP (mmHg) 1.3 ± 1.4 1.3 (-1.8–3.7) 1.00 (P \ 0.001)
Invasive TPVR (104*dynscm-5) 9.1 ± 8.6 8.4 (-16.6–24.6) 0.94 (P \ 0.001)
Echo systolic PAP (mmHg) 3.6 ± 3.6 3.3 (-4.1–9.7) 0.98 (P \ 0.001)
Echo TPVR (ms-1m) 4.9 ± 1.3 4.6 (-5.4–7.3) 0.98 (P \ 0.001)
Echo TPVR (104* dynscm-5) 9.7 ± 8.5 9.0 (-18.4–20.7) 0.95 (P \ 0.001)
IVRT’ (ms) 20.6 ± 27.2 22.2 (-84.6–16.0) 0.89 (P \ 0.001)
PAAT (ms) 2.6 ± 3.5 2.4 (-4.1–9.1) 0.93 (P \ 0.001)
PAD (m/s2) 5.8 ± 5.4 5.3 (-7.0–14.0) 0.98 (P \ 0.001)
Right ventricular area (cm2) 11.2 ± 9.3 9.0 (-14.3–16.2) 0.91 (P \ 0.001)
Right ventricular thickness (mm) 8.9 ± 8.6 5.9 (-15.6–18.3) 0.95 (P \ 0.001)
Values for coefficient of variation (CV) are means ± SD and for mean difference are means and range
See Methods for calculations
PAP pulmonary artery pressure; TPVR total pulmonary vascular resistance; IVRT’ tissue Doppler derived isovolumetric relaxation
time of the right ventricle; PAAT pulmonary artery acceleration time; PAD pulmonary artery deceleration
514 Int J Cardiovasc Imaging (2010) 26:509–518
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algorithms for the evaluation of PAH that may also
have value in the evaluation of PAH in patients.
Invasive PAPs in our study were similar to the
values reported in earlier studies of rats with MCT-
induced PAH [20, 29, 30]. Distinction to the high
yield of non-invasive echocardiography methods, we
measured invasive PAP successfully in only 34 out of
47 cases (72%) with advanced PAH. This experience
is in-line with the success rates reported by other
investigators: 80% at day 21 and 50% at day 35
(personal communication, Dr Hirofumi Sawada,
Stanford University, CA). The difficulty of perform-
ing invasive measurements in animals with advanced
PAH is an important limitation of all invasive
parameters and underscores the importance of inno-
vative non-invasive measurements.
To our knowledge, TPVR has not been studied in
rodents using echocardiography. In our study, echo-
TPVR values predicted invasive TPVR values but
were limited to animals with more advanced PAH
with TR jet. Echo-TPVRs were studied only to check
whether their use would offer relevant and easily
detectable information in this animal model. Both
Echo-TPVR formulas 1 and 4, which are simpler
measurements, were found to be useful when com-
pared to the diagnostic yield of echo-TPVR formula-
2, which is a more complex calculation.
We found tissue Doppler parameter difficult to
measure. This failure may be explained by the fact that
rats have a much thinner right ventricular wall and a
higher heart rate than humans. Additionally, we
noticed that Doppler gain settings have a significant
influence on IVRT’ values. Only 2–4 ms difference in
IVRT’ corresponds to 10–20% change in this param-
eter. IVRT’ values corrected to RR-interval were
similar to the levels observed by Boissiere et al. [26]
(data not shown). Recently, it has been reported that
IVRT’\40 ms has 100% negative predictive value for
PAH in humans [14]. Furthermore, IVRT’ is generally
a measure of right ventricular diastolic function
describing ventricular burden of PAH. Therefore, it
has substantial limitations for use in the measurement
of PAH. Other ultrasound systems with different
filtering algorithms for tissue Doppler signals may
have led to better diagnostic yield of tissue Doppler
technique but this remains to be studied.
Pulmonary artery acceleration time values in our
study were similar to the values observed in earlier
studies of rats with MCT-induced PAH [30, 31].
Jones et al. [30] reported the correlation of 0.84
between PAAT and invasive PAP only in animals
with PAAT between 20 and 32 ms. In our study a
comparable correlation was found even without
excluding values outside this range. Short PAAT
values are likely due to reduced capacitance and the
increased impedance of the pulmonary vascular bed
causing the deceleration to begin at early systole [32].
Furthermore, increased stiffness of pulmonary artery
may cause short PAAT and rapid PAD by increasing
the pulse wave velocity and therefore causing earlier
reflection from the periphery resulting in early
deceleration [33].
Previously, Jones et al. [30] showed that quanti-
fication of TR velocity is usually unsuccessful in rats
Table 3 Diagnostic performance of echocardiographic parameters to detect pulmonary hypertension (mPAP [25 mmHg)
PAAT
\28 ms (%)
PAD
[11.8 m/s2 (%)
PAAT \28 ms and
PAD [11.8 m/s2 (%)
PAAT \28 ms or
PAD [11.8 m/s2
(%)
RV thickness
[0.56 mm (%)
RV area
[0.225 cm2 (%)
Sensitivity 86.4 72.7 68.2 86.4 72.7 82.6
Specificity 87.8 87.8 97.6 78.0 94.3 84.6
Negative
predictive
value
79.2 76.2 93.8 67.9 88.9 76.0
Positive
predictive
value
92.3 85.7 85.1 91.4 84.6 89.2
Accuracy 87.3 82.5 87.3 81.0 86.0 83.9
See Methods for calculations
PAAT pulmonary artery acceleration time; PAD pulmonary artery deceleration; PAP pulmonary artery pressure; RV right ventricle
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with systolic PAP below 65 mmHg. Our data
supports this observation, as we were able to quantify
TR velocity from only one rat with invasive systolic
PAP below 65 mmHg. Jones et al. [30] also demon-
strated a good correlation (r = 0.92) between rat PAP
using this method compared to invasive measure-
ment, but the technique succeeded only in six of 61
animals. In our study, the lack of significant corre-
lation between TR velocity derived PAP compared to
invasive PAP may be explained by the relatively
small range of successful PAP measurements by this
particular echo technique. No other studies have
evaluated intra- or interobserver variabilities of the
invasive PAP or TPVR measurement in the rat model
of PAH. Jones et al. [30] reported the intraobserver
and interobserver variability between 3.0 and 3.5%
for PAAT by a non-standard method of using twice
SD. In our report, all the echocardiographic param-
eters were found to have low intraobserver and
interobserver variability. The exception was IVRT’,
which had a high interobserver variability and also
the quite poor correlation with invasive PAP.
The algorithm of PAAT \28 ms and PAD
[11.8 m/s2 has the best specificity of 97.6% and
the algorithm of PAAT \28 ms or PAD [11.8 m/s2
has the best sensitivity of 82.6% of the studied
parameters to detect significant PAH (of note, PAAT
alone also has the same sensitivity). Parameter with a
high sensitivity is advantageous for detecting estab-
lished disease before treatment and parameter with a
high specificity for excluding animals before further
experiments due to failure in the induction of the
disease. This is a critical issue in translational studies,
as they are usually performed using relatively small
treatment groups and are therefore, especially vul-
nerable for misleading results. The presented algo-
rithms can be employed to ensure disease induction
and improve the verity of the data collected.
There are a number of limitations to our study. First,
echo-TPVR-formula-2 and invasive-TPVR were both
calculated by cardiac outputs derived from non-
invasive method. In this regard, it should be high-
lighted that the purpose of this study was to evaluate
whether simple echocardiographic measurements such
as those used for the calculation of echo-TPVR-1, 3
and 4 would have value when evaluating rat PAH.
Based on our previous published work [25] non-
invasive cardiac output was comparable to the invasive
measurement. Additionally, it is well recognized that
the presence of moderate to severe TR, as observed in
advanced PAH, may lead to inaccurate invasive
thermodilution derived cardiac outputs whereas TR
has no effect on the echocardiographically derived
measurements and this may be preferable as an easier,
more reproducible and non-invasive measure of car-
diac output. Bland–Altman plots from two recent
studies indicate that there may be more differences
between thermodilution and Fick methods derived
cardiac outputs compared to echocardiography and
Fick [34, 35]. Despite this, we do recognize this point
as a limitation of our manuscript but do not believe that
the invasive measurements would have altered the
results of our findings and in fact, since it is very
challenging to make these measurements in rats with
significant PAH, we propose that future studies use the
non-invasive method proposed here to avoid high
animal mortality and allow completion of the research
studies in a timely and cost-effective manner. Second,
agitated saline or contrast agent was not used to
enhance the Doppler signal determining TR velocity,
which might have improved yield of successful
measurements. However, contrast agents in rats
require tail vein cannulation and a separate infusion
pump with agitation capability, and importantly it
would have potentially influenced the non-invasive
nature of our measurements. Third, a correction for
heart rate in PAAT measurement was not used. Finally,
echocardiographically determined TPVR (formula 1)
was not adjusted for right ventricular outflow tract
diameter. However, in another study, this correction
did not lead to a significant change in the correlation
between the methods (r = 0.73 vs. r = 0.71) [13].
In addition, it should be noted that the Bland–
Altman technique is considered ideal when evaluat-
ing agreement between two methods especially when
one is comparing measurements, which are expected
to give the same values in the ideal situation when the
methods do not differ. In our study, only two
variables were suitable for assessment with the
Bland–Altman method, and this has been reported.
Finally, it should be emphasized that observed
values of echocardiographic parameters in this study
can be assumed valid only in rats. It has been shown
that PAAT values are much higher in humans com-
pared to rats due to lower heart rate [36]. PAP was
measured only in animals with chronic pulmonary
hypertension, and our results may not apply to acute
PAH.
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Conclusion
In conclusion, we have shown that non-invasive
echocardiography allows the measurement of several
highly reproducible parameters for evaluation of
PAH in a small animal model of which pulmonary
artery acceleration time and deceleration are the most
practical.
Acknowledgments This study was supported by a grant from
The Foundation for Cardiac Research (KC, TDM and YY) The
Harold Castle Foundation (to YY), The Cardiac Stem Cell
Foundation (to YY) and all the following grants to JWK: Sigrid
Juselius Foundation, Finnish Foundation for Cardiovascular
Research, Paavo Nurmi Foundation, Varsinais-Suomi Regional
Fund of Finnish Cultural Foundation and The Finnish Medical
Foundation.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which
permits any noncommercial use, distribution, and reproduction
in any medium, provided the original author(s) and source are
credited.
References
1. Simonneau G, Robbins IM, Beghetti M, Channick RN,
Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin
MT, Jing ZC, Krowka MJ, Langleben D, Nakanishi N,
Souza R (2009) Updated clinical classification of pul-
monary hypertension. J Am Coll Cardiol 54:S43–S54
2. D’Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH,
Brundage BH, Detre KM, Fishman AP, Goldring RM,
Groves BM, Kernis JT (1991) Survival in patients with
primary pulmonary hypertension. Results from a national
prospective registry. Ann Intern Med 115:343–349
3. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery
JL, Barbera JA et al (2009) Guidelines for the diagnosis
and treatment of pulmonary hypertension: the task force
for the diagnosis and treatment of pulmonary hypertension
of the European society of cardiology (ESC) and the
European respiratory society (ERS), endorsed by the
International society of heart and lung transplantation
(ISHLT). Eur Heart J 30:2493–2537
4. Celermajer DS, Marwick T (2008) Echocardiographic and
right heart catheterization techniques in patients with pul-
monary arterial hypertension. Int J Cardiol 125:294–303
5. Cacciapuoti F (2009) Echocardiographic evaluation of
right heart function and pulmonary vascular bed. Int J
Cardiovasc Imaging 25:689–697
6. Willens HJ, Fertel DP, Qin J, Labrador E, Lowery MH
(2008) Effects of age and pulmonary arterial hypertension
on the different phases of right atrial function. Int J Car-
diovasc Imaging 24:703–710
7. McGoon M, Gutterman D, Steen V, Barst R, McCrory DC,
Fortin TA, Loyd JE, American college of chest physicians
(2004) Screening, early detection, and diagnosis of
pulmonary arterial hypertension: ACCP evidence-based
clinical practice guidelines. Chest 126:14S–34S
8. Abbas AE, Fortuin FD, Schiller NB, Appleton CP, Moreno
CA, Lester SJ (2003) Echocardiographic determination
of mean pulmonary artery pressure. Am J Cardiol 92:
1373–1376
9. Bossone E, Bodini BD, Mazza A, Allegra L (2005) Pul-
monary arterial hypertension: the key role of echocardi-
ography. Chest 127:1836–1843
10. Selimovic N, Rundqvist B, Bergh CH, Andersson B, Pet-
ersson S, Johansson L, Bech-Hanssen O (2007) Assess-
ment of pulmonary vascular resistance by Doppler
echocardiography in patients with pulmonary arterial
hypertension. J Heart Lung Transplant 26:927–934
11. Ristow B, Ali S, Ren X, Whooley MA, Schiller NB (2007)
Elevated pulmonary artery pressure by Doppler echocar-
diography predicts hospitalization for heart failure and
mortality in ambulatory stable coronary artery disease: the
heart and soul study. J Am Coll Cardiol 49:43–49
12. Abbas AE, Fortuin FD, Schiller NB, Appleton CP, Moreno
CA, Lester SJ (2003) A simple method for noninvasive
estimation of pulmonary vascular resistance. J Am Coll
Cardiol 41:1021–1027
13. Vlahos AP, Feinstein JA, Schiller NB, Silverman NH
(2008) Extension of Doppler-derived echocardiographic
measures of pulmonary vascular resistance to patients with
moderate or severe pulmonary vascular disease. J Am Soc
Echocardiogr 21:711–714
14. Brechot N, Gambotti L, Lafitte S, Roudaut R (2008)
Usefulness of right ventricular isovolumic relaxation time
in predicting systolic pulmonary artery pressure. Eur J
Echocardiogr 9:547–554
15. Kjaergaard J, Schaadt BK, Lund JO, Hassager C (2009)
Prognostic importance of quantitative echocardiographic
evaluation in patients suspected of first non-massive pul-
monary embolism. Eur J Echocardiogr 10:89–95
16. Kitabatake A, Inoue M, Asao M, Masuyama T, Tanouchi J,
Morita T, Mishima M, Uematsu M, Shimazu T, Hori M,
Abe H (1983) Noninvasive evaluation of pulmonary
hypertension by a pulsed Doppler technique. Circulation
68:302–309
17. Okamoto M, Miyatake K, Kinoshita N, Sakakibara H,
Nimura Y (1984) Analysis of blood flow in pulmonary
hypertension with the pulsed Doppler flowmeter combined
with cross sectional echocardiography. Br Heart J 51:
407–415
18. Martin-Duran R, Larman M, Trugeda A, Vazquez de Prada
JA, Ruano J, Torres A, Figueroa A, Pajaron A, Nistal F
(1986) Comparison of Doppler-determined elevated pul-
monary arterial pressure with pressure measured at cardiac
catheterization. Am J Cardiol 57:859–863
19. Isobe M, Yazaki Y, Takaku F, Koizumi K, Hara K, Tsu-
neyoshi H, Yamaguchi T, Machii K (1986) Prediction of
pulmonary arterial pressure in adults by pulsed Doppler
echocardiography. Am J Cardiol 57:316–321
20. Meyrick B, Gamble W, Reid L (1980) Development of
Crotalaria pulmonary hypertension: hemodynamic and
structural study. Am J Physiol 239:H692–H702
21. Buermans HP, Redout EM, Schiel AE, Musters RJ, Zu-
idwijk M, Eijk PP, van Hardeveld C, Kasanmoentalib S,
Visser FC, Ylstra B, Simonides WS (2005) Microarray
Int J Cardiovasc Imaging (2010) 26:509–518 517
123
analysis reveals pivotal divergent mRNA expression pro-
files early in the development of either compensated ven-
tricular hypertrophy or heart failure. Physiol Genomics
21:314–323
22. Ghodsi F, Will JA (1981) Changes in pulmonary structure
and function induced by monocrotaline intoxication. Am J
Physiol 240:H149–H155
23. White RJ, Meoli DF, Swarthout RF, Kallop DY, Galaria II,
Harvey JL, Miller CM, Blaxall BC, Hall CM, Pierce RA,
Cool CD, Taubman MB (2007) Plexiform-like lesions and
increased tissue factor expression in a rat model of severe
pulmonary arterial hypertension. Am J Physiol Lung Cell
Mol Physiol 293:L583–L590
24. Chemla D, Castelain V, Humbert M, Hebert JL, Simon-
neau G, Lecarpentier Y, Herve P (2004) New formula for
predicting mean pulmonary artery pressure using systolic
pulmonary artery pressure. Chest 126:1313–1317
25. Penttila¨ J, Snapir A, Kentala E, Koskenvuo J, Posti J,
Scheinin M, Scheinin H, Kuusela T (2006) Estimation of
cardiac output in a pharmacological trial using a simple
method based on arterial blood pressure signal waveform:
a comparison with pulmonary thermodilution and echo-
cardiographic methods. Eur J Clin Pharmacol 62:401–407
26. Boissiere J, Gautier M, Machet MC, Hanton G, Bonnet P,
Eder V (2005) Doppler tissue imaging in assessment of
pulmonary hypertension-induced right ventricle dysfunc-
tion. Am J Physiol Heart Circ Physiol 289:H2450–H2455
27. Bland JM, Altman DG (1986) Statistical methods for
assessing agreement between two methods of clinical
measurement. Lancet 1:307–310
28. Shrout PE, Fleiss JL (1979) Intraclass correlations: uses in
assessing rater reliability. Psychol Bull 86:420–428
29. Hessel MH, Steendijk P, den Adel B, Schutte CI, van der
Laarse A (2006) Characterization of right ventricular
function after monocrotaline-induced pulmonary hyper-
tension in the intact rat. Am J Physiol Heart Circ Physiol
291:H2424–H2430
30. Jones JE, Mendes L, Rudd MA, Russo G, Loscalzo J,
Zhang YY (2002) Serial noninvasive assessment of pro-
gressive pulmonary hypertension in a rat model. Am J
Physiol Heart Circ Physiol 283:H364–H371
31. McMurtry MS, Moudgil R, Hashimoto K, Bonnet S, Mi-
chelakis ED, Archer SL (2007) Overexpression of human
bone morphogenetic protein receptor 2 does not ameliorate
monocrotaline pulmonary arterial hypertension. Am J
Physiol Lung Cell Mol Physiol 292:L872–L878
32. Reuben SR (1971) Compliance of the human pulmonary
arterial system in disease. Circ Res 29:40–50
33. Milnor WR, Conti CR, Lewis KB, O’Rourke MF (1969)
Pulmonary arterial pulse wave velocity and impedance in
man. Circ Res 25:637–649
34. Fisher MR, Forfia PR, Chamera E, Housten-Harris T,
Champion HC, Girgis RE, Corretti MC, Hassoun PM
(2009) Accuracy of Doppler echocardiography in the
hemodynamic assessment of pulmonary hypertension. Am
J Respir Crit Care Med 179:615–621
35. Hoeper MM, Maier R, Tongers J, Niedermeyer J, Hohlfeld
JM, Hamm M, Fabel H (1999) Determination of cardiac
output by the Fick method, thermodilution, and acetylene
rebreathing in pulmonary hypertension. Am J Respir Crit
Care Med 160:535–541
36. Scapellato F, Temporelli PL, Eleuteri E, Corra U, Imparato
A, Giannuzzi P (2001) Accurate noninvasive estimation of
pulmonary vascular resistance by Doppler echocardiogra-
phy in patients with chronic failure heart failure. J Am Coll
Cardiol 37:1813–1819
518 Int J Cardiovasc Imaging (2010) 26:509–518
123
